Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory Board

Neurocentria, Inc., a privately held late-stage biotechnology company developing novel therapies for neurodegenerative and neuropsychiatric disorders, has today announced that Dr. Thomas Südhof, Avram Goldstein Professor in Stanford University School of Medicine and an investigator of the Howard Hughes Medical Institute, has joined the company’s Scientific Advisory Board (SAB). Dr. Südhof’s appointment further strengthens the … Read more

Seegene Technologies, Inc. Announces Name Change to Seegene USA, Inc.

Seegene Technologies, Inc., a subsidiary of Seegene Inc., South Korea’s leading molecular diagnostics company, announced it will change names and begin doing business as Seegene USA, Inc., effective Jan. 1, 2023. The new name reflects an expanding presence in the US for the organization and aligns with a commitment to increase support of the U.S. … Read more

Vivacitas Oncology Welcomes Dr. Jai Grewal, MD, and Expands Its Neuro-Oncology Advisory Board

Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately held oncology company focused on tough-to-treat cancers, is pleased to announce that Dr. Jai Grewal, MD, has agreed to become a new member of their distinguished Neuro-Oncology Advisory Board. Dr. Grewal will be joining Dr. Andrew Lassman, MD, MS, FAAN in the company’s Scientific Advisory Board. Dr. Jai … Read more

BioAccelergy and ExxonMobil to Explore Commercial Scale Development of Bio-Base Stocks

BioAccelergy Ventures has signed a joint-development agreement with ExxonMobil Research and Engineering Company (ExxonMobil) to progress development of a new bio-base stock for lubricants manufacturing from seed and vegetable oil. The multi-year agreement aims to demonstrate the feasibility of producing bio-base stocks at a cost-effective commercial scale to reduce greenhouse gas emissions. BioAccelergy will provide its … Read more

Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

Gb Sciences, a plant-based research and biopharma technology company, has reported positive results from a study of its potential treatment for cytokine release syndrome (CRS), one of the most dangerous complications of COVID-19. With reports of the arrival of the Omicron variant of the coronavirus in multiple countries, the Gb Sciences team plans to move … Read more

Florida Biotech Chooses Tampa for New Company Headquarters

Florida Biotech has selected Tampa for its North American headquarters, research and development, and brand operations, citing the region’s strong talent pool, research universities, strong logistics and growing reputation as a center for biotech and life sciences. Florida Biotech is a sustainable wellness innovation company, developing solutions for industry and home focusing on natural compounds … Read more

Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships

Recognizing the glacial pace of traditional drug research and development processes and the adverse effect of this on patients, biopharmaceutical company Gb Sciences has taken innovative steps to speed up the process and is developing key relationships to further advance the clinical development of its novel, plant-inspired therapies for the prescription drug market. To expedite … Read more

Vivacitas Oncology, Inc. to Present on AR-67 at the Annual 5th Meridian Clinical Trials Conference

Vivacitas Oncology, Inc., a privately-held oncology company focused on tough-to-treat cancers, will present its lead development candidate, AR-67, at this year’s 5th Meridian Clinical Trials (MCT) conference, Nov. 22-23, 2021, via their online platform.  The presentation, “VIVACITAS ONCOLOGY PRESENTS OUR LEAD COMPOUND, AR-67, A NOVEL 3RD GENERATION CAMPTOTHECIN IN RECURRENT GLIOBLASTOMA,” details AR-67 (Topoisomerase I Inhibitor) as a highly … Read more